Roche and AstraZeneca units settle blood drug suit

Roche’s Chugai and AstraZeneca’s Alexion Pharmaceuticals have brought their patent infringement dispute over a treatment for rare, fatal blood diseases to an end.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Chugai settles cancer drug patent dispute with US firm

10 August 2022 Parties to withdraw lawsuit over lung cancer drug | ANDA generic would have displaced sales of patented version in Delaware, said plaintiff.

Americas

AstraZeneca says Mylan, Kindeva infringe another Symbicort patent

28 April 2022 AstraZeneca filed a patent infringement lawsuit against Mylan Pharmaceuticals and Kindeva Drug Delivery on Tuesday, claiming that their generic asthma Symbicort infringes a brand-new patent that was issued the same day.

Big Pharma

Roche asks court for halt of Novartis unit’s generic launch

4 April 2022 Roche’s subsidiary Genentech has asked a Delaware court to block two of Novartis’ units from selling a generic version of the blockbuster lung-disease drug Esbriet.

More features

The Quintara decision: Defining trade secrets in federal cases

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Roche and AstraZeneca units settle blood drug suit

More on this story

Editor's picks

Editor's picks

More features